I updated my little sheet I created as part of my DD for $MDNAF around MDNA11.

- 2/2 patients w/ MSI-H biomarker (still very small patient population), but you can't be 3/2 at this point...
- relative to Proleukin a substantially better safety profile, lower adminstration…

#mnd warrior #mnd efiance #mnd #motorneuronediseaseawareness #mnd awareness #als #als awareness #mnd feminabellator #googlemnd 💙🧡💙🧡 #Proleukin

Who needs Proleukin anyway 💪🏻
#mnd #als

Tolerability is very important in any drug & any idication
$VKTX tolerability looks the best-in-class vs other weight loss drugs.

It reminds me of a very important cancer drug 'Proleukin' that got FDA approval in 1992 as #immunotherapy for the treatment of melanoma & RCC!!! But…

$IOVA if you understand what the company is doing and the drugs that they have, you should go to sleep smiling. They have an amazing TIL and Proleukin combination platform. Right now they have a monopoly. The stock price is not the company and vice versa. Patience.

$IOVA- Expecting significant revenue from Proleukin in 2024. In order for immunotherapy to work, the patients also needed to be infused with IL-2 to boost the strength of Killer T cells. $IOVA has worldwide patent with Proleukin. They will sell this product to companies doing…

Now is the time!!!! 😡
Release the paper and help us access Proleukin!!!!!

As stated in the press release, $MDNAF $MDNA.to WILL present an update from MDNA11 #IL2 trial

Till now, the RR is 23% (while approved Proleukin has ORR 16%) with 3 PR's

We expect to see more patients' data from the Dose-Escalation cohort on recommended dose!

Proleukin Business carve-out financial statements for FY22, FY21, and FY20
$IOVA
#AInvest #Ainvest_Wire #source #analysis #stock
View more: bit.ly/3X4l0XC

#proleukin #mirocal consortium give us a date!

The MND Association Taskforce has identified Proleukin to be considered under the NHS England Drug Repurposing Scheme.

After meeting with the Head of the NHS Drug Repurposing Scheme, we've been advised that the repurposing of Proleukin doesn’t fit within the criteria.

We're…

Chiron:

- One of the first biotech companies. Founded in 1981 by 3 academics: William Rutter, Pablo Valenzuela & Edward Penhoet
- To use genetic engineering for vaccines
- Developing Proleukin (IL-2) among others
- Merging with Cetus and acquired by Novartis in 2006 for $4.5B

It’s not nearly as complicated as is being made out. Proleukin is available now.

If the top priority isn’t resolving issues around #MIROCALS and #Proleukin this seems a wholly missed opportunity.

I'm pleased to share that, in regards to Proleukin, we can, and will, make a formal application to the NHS Drug Repurposing Scheme on behalf of MND patients.

We've also been offered the opportunity for further discussions and we have requested a meeting.

Read our update below.

Thankful for unitedtoendmnd
🙏🏻❤️
Proleukin Update Statement – We are United2EndMND – Changing the conversation united2endmnd.org/2023/08/15/pro…

Clinigen is delighted to announce it has entered into an agreement to divest Proleukin® to Iovance Biotherapeutics for £166.7 million.

The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties.

Find out more:
clinigengroup.com/news/news-cont…

If we had transparency we've requested for months on process followed by #Mirocals Consortium to select commercial partner #Iltoo , it would help. Why a small company? Why a NEW drug when trial drug #Proleukin already available? Lessons MUST be learned for future trials-see image

What a year. Kev and Kenny Logan challenges. Knighthoods all round I say. But still we wait for the release of the data #mirocals #proleukin

First of all with #IL2 we need safety since the only FDA approved IL-2 drug Proleukin is very toxic & used in a limited cases.
So, $MDNAF had mostly Grade-1/2 TRAEs & very little Grade-3, no Grade-4 or 5.

Medicenna is the only co. started showing PR's in dose-escalation arm &…